Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 70710-1411

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 70710-1411). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (77554fd4 A569 4180 9a5f E51962f8524b 01)

Chemical structure of BORTEZOMIB, depicting its molecular arrangement including boronic acid and peptide components, consistent with the generic drug BORTEZOMIB used in human prescription formulations.*

FDA Label Image

Image (77554fd4 A569 4180 9a5f E51962f8524b 02)

A Kaplan-Meier survival curve showing the percentage of patients over time (months) comparing two treatment groups, Vc-MP and MP. The graph displays patient survival declining over 24 months, with Vc-MP group survival consistently higher than MP group. A p-value of 0.000002 indicates statistical significance. The chart includes numbers of patients at risk for each group over time.*

FDA Label Image

Image (77554fd4 A569 4180 9a5f E51962f8524b 03)

A Kaplan-Meier survival curve showing the percentage of patients over time (in months) comparing two treatment groups labeled Vc-MP and MP. The graph includes the number of patients at risk at various time points and a notation indicating a p-value less than 0.05 from a log-rank test.*

FDA Label Image

Image (77554fd4 A569 4180 9a5f E51962f8524b 04)

A Kaplan-Meier survival curve chart comparing the proportion of patients over time (in days) for Bortezomib and Dexamethasone treatments. The chart shows two lines, with Bortezomib having a higher proportion of patients remaining over time compared to Dexamethasone. Timepoints with patient counts and a p-value from a log-rank test are indicated below the x-axis.*

FDA Label Image

Image (77554fd4 A569 4180 9a5f E51962f8524b 05)

A survival curve graph comparing the proportion of patients over time (days) between treatment with Bortezomib and Dexamethasone. The graph includes sample sizes at various time points, a p-value annotation indicating statistical significance (p<0.05), and uses separate color-coded lines to represent each treatment group.*

FDA Label Image

Image (77554fd4 A569 4180 9a5f E51962f8524b 06)

A survival curve chart comparing two treatment groups, VcR-CAP and R-CHOP, over time in months. The y-axis represents the percentage of patients, and the x-axis shows time up to 66 months. The chart includes a log rank test with a p-value of less than 0.001 and a table below indicating the number of subjects at risk at different time points.*

FDA Label Image

Image (77554fd4 A569 4180 9a5f E51962f8524b 07)

A Kaplan-Meier survival curve comparing the percentage of subjects alive over months from randomization between two treatment groups, VcR-CAP and R-CHOP. The graph includes a hazard ratio with 95% confidence interval, and a table showing the number of subjects at risk at various time points for each group.*

FDA Label Image

Vial Label (77554fd4 A569 4180 9a5f E51962f8524b 08)

Bortezomib for Injection 3.5 mg/vial powder label for intravenous or subcutaneous use. The label includes storage instructions, usage information, and manufacturer details, stating it is made by Zydus Hospira Oncology Pvt. Ltd. in India and distributed by Zydus Pharmaceuticals USA Inc. The vial contains 3.5 mg bortezomib and 35 mg mannitol.*

FDA Label Image

Carton (77554fd4 A569 4180 9a5f E51962f8524b 09)

This is the packaging label for Bortezomib for Injection, 3.5 mg per vial, a lyophilized powder for intravenous or subcutaneous use. The label includes reconstitution instructions for subcutaneous and intravenous injections, manufacturer details (Zydus Hospira Oncology Pvt. Ltd., India) and distributor (Zydus Pharmaceuticals USA Inc.). Box indicates one single-dose vial, Rx only.*

FDA Label Image

Carton (inside Flap) (77554fd4 A569 4180 9a5f E51962f8524b 10)

A flat carton template for BORTEZOMIB 1 mg/mL injection powder, lyophilized for solution by Zydus Pharmaceuticals USA Inc. The label includes reconstitution information with two sections: Subcutaneous injection requiring 1.4 mL of 0.9% sodium chloride to make 2.5 mg/mL concentration, and Intravenous injection requiring 3.5 mL of 0.9% sodium chloride to make 1 mg/mL concentration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.